Design-to-Build Biofoundry Board Challenger — Synthetic Biology

The mandate

The board returns each quarter to whether the biofoundry can scale partner programmes without losing the precise relationship among design intent, sequence, physical construct, host strain, build protocol, assay and learning. Utilisation figures look strong, but rework, biological variability, customer restrictions and biosafety review are absorbed inconsistently. Capital expansion cannot rest on machine throughput alone.

The challenger will reserve three days monthly for committee preparation, platform evidence review and sessions with scientific and partner leaders, and will attend four Hyderabad board meetings. A written view on a declared strain or partner-evidence event is due within two Indian business days. Laboratory execution, diligence or programme delivery requires a separately approved scope.

The appointment runs for nine months from February 2027. Management will face an unseen partner-transfer and strain-correction scenario during month seven. The board may approve one three-month renewal for a named capacity investment or collaboration decision; unspent days expire, and the appointment cannot drift into standing scientific supervision or implementation support.

The challenger has no line authority, executive authority, scientific-signing right, biosafety role, partner-negotiation mandate, capital vote or laboratory command. Management decides programmes; authorised scientists and biosafety officers approve work; the board allocates capital. Advice cannot be described as strain validation, containment assurance, freedom-to-operate opinion or proof of industrial performance.

Interests involving biofoundries, DNA suppliers, automation vendors, cloud design platforms, strain-engineering companies, customers or investors must be disclosed as conflicts. No direct competitor board may run concurrently; one non-overlapping research appointment requires chair approval. Partner sequences, strains and negative results cannot be reused as external benchmarks or inform another portfolio company.

Why the board wants this voice

Directors have deep science and venture experience but lack an operator who has balanced biological variability, automation economics and multi-customer confidentiality at scale. The missing voice can challenge whether the platform truly learns across programmes without leaking rights or flattening biological context, while remaining outside scientific and commercial authority.

What you will own

• Press the board to trace design intent, sequence, physical construct, strain, build, assay, result, learning and partner restriction.
• Test capacity claims for failed builds, biological repeats, cleaning, containment, material logistics and scientist intervention hidden by utilisation metrics.
• Challenge cross-programme learning where customer intellectual property, biosafety classification or host context limits legitimate reuse.
• Frame scenarios involving sequence correction, mislabeled construct, contaminated run, partner withdrawal, automation outage and disputed result ownership.
• Probe capital gates for reproducibility, marginal cycle economics, constrained equipment, partner pull and credible scale-down triggers.
• Examine supplier dependence across DNA, automation, analytics and design software, including export, continuity and exit obligations.
• Coach directors to request decision-grade biological and operating evidence rather than polished design-build-test-learn cycle counts.

Candidate qualifications

• Held senior biofoundry, synthetic-biology platform or industrial biotechnology authority across computational design and automated wet-lab execution.
• Governed design, sequence, construct, strain, protocol and assay lineage through biological failure, correction and partner transfer.
• Exposed capacity economics after accounting for repeats, contamination, scientist intervention, constrained instruments and biosafety controls.
• Structured multi-partner learning without leaking sequence, strain, assay or negative-result rights across confidential programmes.
• Presented scale, stop and partnership choices to boards under scientific uncertainty, capital scarcity and ambitious automation narratives.
• Managed conflicts among biofoundries, suppliers, customers, investors and research institutions while protecting unpublished biological assets.

Non-negotiables

• Can attend all four Hyderabad board sessions and respond within two business days to a declared strain-evidence event.
• Will disclose every biofoundry, DNA, automation, platform, customer, investor and research interest before data access.
• Accepts literal absence of line, executive, scientific, biosafety, partner, laboratory and capital authority.
• Must evidence scaled design-build-test operations; general biotechnology strategy or computational-design exposure does not qualify.

1. 49 words maximum. Describe a biofoundry scale claim that changed after biological repeats and scientist intervention were counted.
2. 49 words maximum. Which current biofoundry, supplier, customer, investor or research interests require board disclosure?
3. 49 words maximum. How would you preserve reusable learning without crossing a partner’s sequence or strain rights?